| Project/Area Number |
24650645
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
TAHARA Hidetoshi 広島大学, 大学院医歯薬保健学研究院, 教授 (00271065)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OCHIYA Takahiro 国立がん研究センター研究所, 分子細胞治 療研究分野, 分野長 (60192530)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | がん / マイクロRNA / 核酸医薬 / ドラッグデリバリー / エクソソーム |
|---|
| Research Abstract |
We found that macrophage is highly secreted exosome like particle with exosome maker such as CD63 and CD9 and Alix. We made CD63-GFP fusion protein and cloned into lenti-virus vector. CD63-GFP lenti-virus is infected to cancer and macrophage and established cell line stably expressing CD63-GFP fusion protein. We isolated exosome from these cell lines and purified by ultra-centrifugation, and found that these purified exosome is successfully derived to recipient cells. These results suggest that exosome can be a tools for novel DDS of microRNAs.
|
